For the Inventor, By the Inventor

Enter assignee name

Kirkland, Canada

Merck Canada Inc.

Calculating rank

USPTO Granted Patents = 40

% Expired Patents = 17.5

CIPO Patents = 4

EPO Patents = 54

Forward Citations = 198

Loading Chart...

Loading Chart...

189 inventors (with patents filed for the assignee):

Alan B Northrup (11 out of 36 patents)

John Michael Ellis (9 out of 19 patents)

Michael D Altman (8 out of 59 patents)

4. Christian Beaulieu (8 out of 11 patents)

5. Jason Burch (8 out of 13 patents)

6. Andrew M Haidle (8 out of 25 patents)

7. Oscar Miguel Moradei (7 out of 32 patents)

8. Vouy Linh Truong (7 out of 11 patents)

9. Solomon D Kattar (7 out of 28 patents)

10. Michael Hale Reutershan (6 out of 22 patents)

11. Kerrie Spencer (6 out of 11 patents)

12. Michelle R Machacek (6 out of 35 patents)

13. Anthony Donofrio (6 out of 15 patents)

14. Sheldon N Crane (6 out of 9 patents)

15. Kaleen Konrad Childers (6 out of 13 patents)

Core Competencies:

HIV Protease Inhibitors

Spleen Tyrosine Kinase

CRTH2 Receptor Antagonists

Cysteine Protease Inhibitors

Renin Inhibitors

Aminopyrimidines

Tetrahydronaphthyridine Derivatives

Triazolyl Derivatives

Spiro Compounds

Indole Derivatives

Thiazole-Substituted Compounds

Non-Nucleoside Reverse Transcriptase Inhibitors

40 patents: Sort by Forward Citations

1. 10072003 - Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2018-09-11),

2. 9994587 - HIV protease inhibitors (2018-06-12),

3. 9834526 - HIV protease inhibitors (2017-12-05),

4. 9822107 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-11-21),

5. 9745295 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-08-29),

6. 9737545 - HIV protease inhibitors (2017-08-22),

7. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

8. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

9. 9376418 - Substituted pyridine spleen tyrosine kinase (SYK) inhibitors (2016-06-28),

10. 9353066 - Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors (2016-05-31),

11. 9315475 - HIV protease inhibitors (2016-04-19),

12. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

13. 9187415 - Sulfonamides as HIV protease inhibitors (2015-11-17),

14. 9168248 - Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase (2015-10-27),

15. 9145391 - Bipyridylaminopyridines as Syk inhibitors (2015-09-29),

Company Overview

Merck Canada Inc., headquartered in Kirkland, CA, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative therapies. The company specializes in a range of core technology areas, including HIV protease inhibitors and various receptor antagonists, which are pivotal in treating complex health conditions. With a commitment to advancing healthcare, Merck Canada is dedicated to research that addresses unmet medical needs and enhances patient outcomes across diverse therapeutic domains.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

40 Patents

#5 in Kirkland

#345 in Canada

#17,098 in the World

Kirkland, Canada

Merck Canada Inc.

Forward Citations = 198

189 inventors:

Alan B Northrup (11 out of 36 patents)

John Michael Ellis (9 out of 19 patents)

Michael D Altman (8 out of 59 patents)

4. Christian Beaulieu (8 out of 11 patents)

5. Jason Burch (8 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Canada Inc.. Retrieved from https://idiyas.com/company/merck-canada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…